Inhibitors of VEGF (vascular endothelial growth factor)/VEGFR2 (vascular endothelial growth
factor receptor 2) are commonly used in the clinic, but their beneficial effects are only …

Cancer immunotherapy (CIT) with antibodies targeting the programmed cell death 1 protein
(PD-1)/programmed cell death 1 ligand 1 (PD-L1) axis have changed the standard of care in …

Pathological angiogenesis is a hallmark of cancer and a therapeutic target. Vascular
endothelial growth factor A (VEGFA) and angiopoietin-2 (ANGPT2; also known as ANG2) …

The effectual clinical benefits of immune checkpoint inhibitor (ICI) are hampered by a high
rate of innate resistance, and VEGFA may contribute to ICI treatment resistance. In this study …

Vascular endothelial growth factor A is known to play a central role in tumor angiogenesis.
Several studies showed that VEGF-A is also an immunosuppressive factor. In tumor-bearing …

Immunotherapy has emerged as a major therapeutic modality in oncology. Currently,
however, the majority of patients with cancer do not derive benefit from these treatments …

Simple Summary Although VEGF-A is well characterized as the principal player of cancer
angiogenesis, new data on the interplay with other components of the tumor …

Immunotherapy has recently emerged as a novel strategy for treating different types of solid
tumors, with promising results. However, still a large fraction of patients do not primarily …

Vascular endothelial growth factor-A (VEGF) is the predominant angiogenic factor that is
expressed in solid tumors. Besides its critical function in mediating tumor angiogenesis …

The critical role of angiogenesis in promoting tumor growth and metastasis has been well
established scientifically, and consequently blocking this pathway as a therapeutic strategy …